Use of recombinant factor VIIA for control of combat-related haemorrhage.
The authors should be congratulated for presenting their negative results. The success rate of approximately 70% in both groups is the same as that reported in numerous case series and registers supporting the “efficacy” of rFVIIa in various contexts. Unfortunately, despite three negative randomized controlled trials in trauma (two published, one unpublished), rFVIIa continues to be used for this indication.
– Jean-Franois Hardy